Multiple Dose Study Of PF-05231023 In Obese Adult Subjects

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus (T2DM)

In brief

This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.

Key facts

Study ID

NCT01923389

Run by

Pfizer

People needed

4

Starts

2013-09-01

Expected to finish

2013-12-01

Last updated by the study team

2014-09-17

Who can join

Age: 21 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female subjects of non-childbearing potential between the ages of 21 and 70.
• Subjects with a BMI of 30 to 45.4 kg/m2 and total body weight >110 lbs.

You may not qualify if…

• Recent (6 months) unstable concurrent disease.
• History of allergic disease or drug allergies.
• Any condition affecting food consumption or absorption.

Where it is running

• Pfizer Investigational Site — Orlando, Florida, United States
• Pfizer Investigational Site — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.